Signature of contracts for full development of Vega small launcher and P80

February 26, 2003

Today ESA signed a contract with the ELV company for completion of the development phase of the Vega European small launcher programme, and CNES signed, on behalf of ESA, a contract with FiatAvio for development of the P80 advanced solid propulsion stage and demonstrator.

The contracts were signed in Colleferro (Rome), on the FiatAvio industrial park, in the presence of representatives of the Italian Government, ESA, ASI, Arianespace, CNES and ELV.

Step 1 of the Vega small launcher programme was decided by the ESA Council in June 1998. Funding for both the Vega and P80 programmes was approved by the participating states in December 2000.

Italy is the leading contributor to the Vega programme with 65 %, other participants being Belgium (5.63%), France (12.43%), the Netherlands (3.5%), Spain (5%), Sweden (0.8%) and Switzerland (1.34%). Belgium, France, Italy and the Netherlands are also contributing to the P80 programme.

ELV is the prime contractor for the Vega launcher. Its shareholders are FiatAvio (70%) and the Italian space agency, ASI (30%). FiatAvio is the prime contractor for the P80.

The Vega small launcher configuration consists of 3 solid stages: the P80 first stage, the Zefiro 23 second stage, the Zefiro 9 third stage and an upper liquid propulsion module, called AVUM.

Vega's target lift capability is 1500 kg and it will inject its payload into a circular orbit at 700 km altitude. The launch base to be used for Vega is the European Spaceport at Kourou in French Guiana.

Arianespace will be the commercial operator for Vega. The first qualification launch is planned for mid-2006, with an expected frequency of 3 to 4 launches a year.

The P80 has twofold objectives: to serve as the first stage of the launcher and to develop new technologies for the future A5 solid booster.

An integrated project team (IPT), comprising staff from ESA and the Italian and French space agencies (ASI and CNES), will manage the Vega launcher contract and ensure overall system coherence. It is to be located at the ESA establishment near Rome, ESRIN.

The P80 contract will be managed, under the authority of the IPT, by CNES through a dedicated project team, including ESA and ASI staff. The P80 team is to be located at the CNES establishment in Evry, near Paris.

The values of these development contracts are: EUR 221m for the Vega launcher, and EUR 40m for the P80.

European Space Agency

Related Development Articles from Brightsurf:

What jigsaw puzzles tell us about child development
New research shows that children only learn to do jigsaw puzzles once they have reached a certain stage of development.

Simulating wind farm development
Engineers have devised a model to describe how, in the process of establishing wind farms, interactions between developers and landowners affect energy production costs.

A new approach to measuring inequalities in development
A new study by researchers from IIASA and Hong Kong University of Science and Technology for the first time systematically explored and compared the use of the Human Life Indicator as a viable alternative to the conventional Human Development Index as a means of measuring progress in development.

Reconstructing the clock of human development
Researchers used iPS cells to reconstructed the human 'segmentation clock,' a key point in early embryonic development that determines how the body gets segmented.

Mother nature and child development
A world first review of the importance of nature play could transform children's play spaces, supporting investment in city and urban parks, while also delivering important opportunities for children's physical, social and emotional development.

Citizen science for sustainable development
Monitoring progress on the UN Sustainable Development Goals requires a huge amount of data.

A molecular 'atlas' of animal development
Scientists have studied the nematode worm Caenorhabditis elegans for decades, making essential contributions to basic science.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

New knowledge on the development of asthma
Researchers at Karolinska Institutet in Sweden have studied which genes are expressed in overactive immune cells in mice with asthma-like inflammation of the airways.

Read More: Development News and Development Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to